Wang Lai 4

What Happened Wang Lai, President and Global Head of R&D at BeOne Medicines (ONC), disposed of 1,367 American Depositary Shares (ADS) on June 8, 2026. The sales consisted of 1,327 ADS at a weighted average price of $269.34 (proceeds $357,418) and 40 ADS at $270.73 (proceeds $10,829), totaling approximately $368,247. These sales were effected pursuant to a mandatory tax withholding provision tied to the vesting of restricted share units (RSUs), not an open-market discretionary sale.

Key Details

• Transaction dates: June 8, 2026; Form 4 filed June 10, 2026 (timely filing).
• Shares sold: 1,327 ADS @ weighted avg $269.34 (range $268.88–$269.80) and 40 ADS @ $270.73; total 1,367 ADS; total proceeds ≈ $368,247.
• Reason: F6 — sale made to satisfy tax withholding on RSU vesting (1/4 vests each June 5 anniversary beginning 2024; accelerated vesting on certain change-in-control terminations).
• ADS conversion: F5 — each ADS represents 13 ordinary shares.
• Weighted-average details: F7 — larger block sold in multiple transactions at varying prices; issuer can provide detailed per-price breakdown on request.
• Other footnotes: F1–F4 relate to holdings via Wang Holdings LLC and an RMB Shares employee participation plan; Wang disclaims beneficial ownership of certain RMB Shares held through the plan.
• Shares owned after the transaction: Not specified in the provided excerpt.

Context This was a withholding sale to cover taxes on vested RSUs (common administrative practice) rather than a discretionary sell signal. Footnotes clarify ADS structure and the insider’s participation in an RMB Shares employee plan; no indication of late filing.